+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Spinal Muscular Atrophy Treatment Market - Global Forecast to 2030- Product Image
Spinal Muscular Atrophy Treatment Market - Global Forecast to 2030- Product Image
Sale

Spinal Muscular Atrophy Treatment Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012079
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Spinal Muscular Atrophy Treatment Market grew from USD 1.85 billion in 2024 to USD 2.15 billion in 2025. It is expected to continue growing at a CAGR of 15.44%, reaching USD 4.38 billion by 2030.

Spinal muscular atrophy (SMA) has transitioned from a relentlessly progressive neurodegenerative condition to a landscape infused with hope, driven by breakthroughs in molecular medicine. Over the past decade, the convergence of gene therapy, antisense oligonucleotide technology, and optimized supportive care protocols has reshaped prognosis and care pathways. This executive summary illuminates pivotal developments in SMA treatment, crystallizes the impact of impending policy shifts, and distills strategic insights for stakeholders. By weaving together clinical innovations, market dynamics, and regulatory considerations, this report offers a coherent foundation for decision-making. Through a synthesis of segmentation analyses, regional trends, and corporate strategies, we aim to equip industry leaders, payers, and clinician-investigators with a nuanced understanding of current challenges and emerging opportunities. As we embark on this overview, the intersection of science, policy, and patient-centric care will guide our exploration of SMA’s evolving therapeutic frontier.

Transformative Shifts Redefining SMA Treatment Paradigms

The SMA landscape is experiencing a tectonic shift as novel modalities transition from bench to bedside. Gene therapy’s ascent, exemplified by onasemnogene abeparvovec’s pioneering single-dose approach, underscores a broader move toward curative intent rather than symptomatic management. Concurrently, enzyme replacement therapies such as nusinersen and risdiplam are redefining standards of care, achieving improvements in motor function and survival milestones. Beyond these core modalities, the maturation of supportive care-including nutritional optimization, respiratory support, and adaptive devices-enhances quality of life and long-term outcomes. The research pipeline remains robust, with emerging antisense oligonucleotides and monoclonal antibody candidates promising incremental gains. Moreover, the shift toward personalized treatment regimens, informed by patient age, disease stage, and delivery preferences, signals a new era of tailored interventions. Together, these transformative shifts are forging a dynamic, patient-centered ecosystem poised to rewrite SMA’s trajectory.

Assessing the Implications of 2025 US Tariff Changes on SMA Therapies

The United States’ tariff adjustments slated for 2025 carry significant implications for SMA therapeutics, particularly given the global supply chains underpinning biologics and gene therapy vectors. Increased import duties on raw materials and biologic intermediates could elevate production costs for high-value therapies, potentially intensifying pricing pressures. Conversely, amended tariff regimes may incentivize domestic manufacturing investments, accelerating capacity expansions in gene therapy vector production and antisense oligonucleotide synthesis. Payers and health systems will need to navigate a nuanced cost environment where unit prices for single-dose curative therapies and chronic administration agents respond to these policy shifts. At the same time, multinational manufacturers might reconsider global distribution strategies, balancing tariff-induced cost inflations against market access objectives. Ultimately, the cumulative impact of 2025 tariffs will reverberate across drug economics, reimbursement negotiations, and supply chain resilience, demanding proactive engagement from stakeholders to safeguard patient access.

Key Segmentation Insights Shaping SMA Treatment Dynamics

Disaggregating the SMA market by treatment type reveals that enzyme replacement therapy (ERT) encompasses both established agents like nusinersen and risdiplam alongside a cohort of emerging therapies still traversing clinical and regulatory milestones. Gene therapy bifurcates into approved vectors such as onasemnogene abeparvovec and a robust research pipeline exploring next-generation gene editing and delivery platforms. Supportive care, an equally critical pillar, spans nutritional support programs, specialized physical therapy regimens, and advanced respiratory support to mitigate secondary complications.

Mapping the market by stage of disease highlights diverging clinical imperatives. Type 1 (infantile) cases demand early intervention protocols and rigorous progression monitoring, whereas Type 2 (intermediate) management focuses on mobility aids and orthopedic interventions to preserve function. Type 3 (juvenile) patients benefit from tailored physical activity adaptations and symptomatic therapies, and Type 4 (adult) cohorts leverage adaptive devices and comprehensive therapeutic management to maintain autonomy.

Examining drug typology, biologics dominate with antisense oligonucleotides and monoclonal antibodies leading development efforts. Biosimilars are carving out a growing market segment, with marketed biosimilars providing cost-effective alternatives and pipeline developments promising expanded access. Small molecules complement these modalities, with approved drugs delivering oral convenience and a slate of clinical trials expanding the small-molecule portfolio.

End-user segmentation underscores distinct service requirements across home care settings-where family caregivers and home health agencies implement day-to-day interventions-versus pediatric hospitals and specialty centers that deliver intensive clinical oversight. Pharmaceutical companies balance commercial marketing drives with research and development imperatives, while research institutions including academic centers and private labs propel innovation through early discovery and translational research.

Delivery route considerations further refine strategic positioning. Intrathecal administration, performed in daycare centers and hospital settings, remains the gold standard for certain antisense therapies. Intravenous administration, increasingly offered via home infusion services and hospital administration networks, enhances patient convenience. Oral formulations, spanning liquid and solid dosage forms, address adherence challenges and broaden treatment accessibility for diverse patient populations.

Age group analysis reveals that infants and neonates-targeted for early curative interventions-contrast with school-age children and preschoolers receiving supportive and symptomatic therapies. Adolescents, divided into teenagers and young adults, face unique transitional care needs, while adults and older adults require adaptive devices and long-term therapeutic management to sustain functional independence.

Regional Nuances Impacting SMA Treatment Adoption and Access

The Americas continue to lead in SMA therapeutic adoption, driven by robust reimbursement frameworks and early access programs enabling rapid uptake of gene therapies and antisense treatments. North America’s mature biotech infrastructure bolsters domestic manufacturing capacity, partially insulating supply chains from tariff-related disruptions.

In Europe, the Middle East and Africa (EMEA), heterogeneous healthcare funding models influence market penetration. Western Europe’s centralized health authorities negotiate value-based pricing for high-cost therapies, whereas emerging markets in Eastern Europe and select Middle Eastern nations pursue tiered access strategies, balancing budget constraints against clinical imperatives. Africa remains nascent in SMA care infrastructure, with pilot projects focusing on awareness and diagnostic capacity building.

The Asia-Pacific region exhibits a dual trajectory: established markets such as Japan and Australia are adopting advanced therapies through national reimbursement schemes, while emerging markets in Southeast Asia and India emphasize cost-effective biosimilars and small-molecule candidates. Local manufacturing partnerships and public-private collaborations are accelerating regional production capabilities to meet growing demand and mitigate import dependencies.

Leading Companies Driving Innovation in SMA Therapeutic Development

Pharmaceutical giants such as Astellas Pharma Inc. and Biogen Inc. anchor the market with flagship products and broad R&D portfolios, while Catalyst Pharmaceuticals, Inc. and Cytokinetics, Incorporated contribute specialized therapies and novel pipeline candidates. F. Hoffmann-La Roche Ltd. leverages its immunology expertise to expand monoclonal antibody approaches, and Ionis Pharmaceuticals, Inc. remains at the forefront of antisense oligonucleotide innovation. Diagnostics leader Natera Inc. enhances SMA patient stratification through cutting-edge genetic screening tools.

Emerging players including NMD PHARMA A/S and Scholar Rock, Inc. introduce differentiated mechanisms of action, while established multinationals Novartis AG and Novo Nordisk A/S scale gene therapy platforms and oral small-molecule franchises. PerkinElmer, Inc. supports early detection and monitoring through advanced diagnostic assays, and Pfizer Inc. integrates SMA treatments into its broader rare disease strategy. PTC Therapeutics, Inc. advances translational research, and Takeda Pharmaceutical Company Limited deploys global commercialization expertise to extend patient reach.

Actionable Recommendations for Industry Leaders in SMA Care

Industry leaders should integrate end-to-end value chain analyses to anticipate tariff-induced cost variances and adjust pricing models accordingly. Strategic alliances between gene therapy developers and contract manufacturing organizations can fortify supply resilience and reduce time-to-market for high-impact products. Tailored patient support programs, especially for home infusion and oral therapy adherence, will differentiate service offerings and enhance outcomes.

Investments in region-specific market access teams, equipped to navigate diverse reimbursement landscapes in the Americas, EMEA, and Asia-Pacific, are crucial for maximizing therapy adoption. Cross-functional collaboration among R&D, regulatory, and commercial functions will accelerate pipeline progression by aligning clinical trial designs with payer evidence requirements. Finally, leveraging real-world evidence from adaptive device utilization and long-term outcome studies can inform value-based contracting and fortify stakeholder confidence.

Conclusion: Navigating Future Challenges and Opportunities in SMA

The SMA treatment arena stands at an inflection point where science, policy, and patient advocacy converge to redefine care standards. As gene therapies and next-generation antisense agents advance, the industry must remain vigilant to regulatory and tariff shifts that influence market dynamics. Segmentation insights underscore the importance of adaptive strategies across treatment types, disease stages, drug classes, delivery routes, and patient demographics. Regional and corporate analyses reveal both opportunities for expansion and challenges in equitable access.

By adopting a holistic perspective that integrates clinical innovation with pragmatic market planning, stakeholders can navigate the complex SMA ecosystem. Continued investment in personalized care pathways, supply chain resilience, and value-based partnerships will ensure that transformative therapies reach all eligible patients. In doing so, the industry can fulfill the promise of durable improvements and, ultimately, disease modification.

Market Segmentation & Coverage

This research report categorizes the Spinal Muscular Atrophy Treatment Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Enzyme Replacement Therapy
    • Emerging Therapies
    • Nusinersen
    • Risdiplam
  • Gene Therapy
    • Onasemnogene Abeparvovec
    • Research Pipeline
  • Supportive Care
    • Nutritional Support
    • Physical Therapy
    • Respiratory Support
  • Type 1 (Infantile)
    • Early Intervention
    • Progression Monitoring
  • Type 2 (Intermediate)
    • Mobility Management
    • Orthopedic Interventions
  • Type 3 (Juvenile)
    • Physical Activity Adaptation
    • Symptomatic Treatment
  • Type 4 (Adult)
    • Adaptive Devices
    • Therapeutic Management
  • Biologics
    • Antisense Oligonucleotides
    • Monoclonal Antibodies
  • Biosimilars
    • Marketed Biosimilars
    • Pipeline Developments
  • Small Molecules
    • Approved Drugs
    • Clinical Trials
  • Home Care Settings
    • Family Caregivers
    • Home Health Agencies
  • Hospitals
    • Pediatric Hospitals
    • Specialty Centers
  • Pharmaceutical Companies
    • Commercial Marketing
    • Research and Development
  • Research Institutions
    • Academic Research
    • Private Research Labs
  • Intrathecal Administration
    • Daycare Centers
    • Hospital-Based Care
  • Intravenous Administration
    • Home Infusion Services
    • Hospital Administration
  • Oral Administration
    • Liquid Formulations
    • Solid Formulations
  • Adolescents
    • Teenagers
    • Young Adults
  • Adults
    • Older Adults
    • Young Adults
  • Children
    • Preschool Kids
    • School Age
  • Infants
    • Babies
    • Neonates

This research report categorizes the Spinal Muscular Atrophy Treatment Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Spinal Muscular Atrophy Treatment Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Astellas Pharma Inc.
  • Biogen Inc.
  • Catalyst Pharmaceuticals, Inc.
  • Cytokinetics, Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Natera Inc.
  • NMD PHARMA A/S
  • Novartis AG
  • Novo Nordisk A/S
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Scholar Rock, Inc.
  • Takeda Pharmaceutical Company Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Spinal Muscular Atrophy Treatment Market, by Treatment Type
8.1. Introduction
8.2. Enzyme Replacement Therapy
8.2.1. Emerging Therapies
8.2.2. Nusinersen
8.2.3. Risdiplam
8.3. Gene Therapy
8.3.1. Onasemnogene Abeparvovec
8.3.2. Research Pipeline
8.4. Supportive Care
8.4.1. Nutritional Support
8.4.2. Physical Therapy
8.4.3. Respiratory Support
9. Spinal Muscular Atrophy Treatment Market, by Stage Of Disease
9.1. Introduction
9.2. Type 1 (Infantile)
9.2.1. Early Intervention
9.2.2. Progression Monitoring
9.3. Type 2 (Intermediate)
9.3.1. Mobility Management
9.3.2. Orthopedic Interventions
9.4. Type 3 (Juvenile)
9.4.1. Physical Activity Adaptation
9.4.2. Symptomatic Treatment
9.5. Type 4 (Adult)
9.5.1. Adaptive Devices
9.5.2. Therapeutic Management
10. Spinal Muscular Atrophy Treatment Market, by Drug Type
10.1. Introduction
10.2. Biologics
10.2.1. Antisense Oligonucleotides
10.2.2. Monoclonal Antibodies
10.3. Biosimilars
10.3.1. Marketed Biosimilars
10.3.2. Pipeline Developments
10.4. Small Molecules
10.4.1. Approved Drugs
10.4.2. Clinical Trials
11. Spinal Muscular Atrophy Treatment Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.2.1. Family Caregivers
11.2.2. Home Health Agencies
11.3. Hospitals
11.3.1. Pediatric Hospitals
11.3.2. Specialty Centers
11.4. Pharmaceutical Companies
11.4.1. Commercial Marketing
11.4.2. Research and Development
11.5. Research Institutions
11.5.1. Academic Research
11.5.2. Private Research Labs
12. Spinal Muscular Atrophy Treatment Market, by Delivery Route
12.1. Introduction
12.2. Intrathecal Administration
12.2.1. Daycare Centers
12.2.2. Hospital-Based Care
12.3. Intravenous Administration
12.3.1. Home Infusion Services
12.3.2. Hospital Administration
12.4. Oral Administration
12.4.1. Liquid Formulations
12.4.2. Solid Formulations
13. Spinal Muscular Atrophy Treatment Market, by Age Group
13.1. Introduction
13.2. Adolescents
13.2.1. Teenagers
13.2.2. Young Adults
13.3. Adults
13.3.1. Older Adults
13.3.2. Young Adults
13.4. Children
13.4.1. Preschool Kids
13.4.2. School Age
13.5. Infants
13.5.1. Babies
13.5.2. Neonates
14. Americas Spinal Muscular Atrophy Treatment Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Spinal Muscular Atrophy Treatment Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Spinal Muscular Atrophy Treatment Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Astellas Pharma Inc.
17.3.2. Biogen Inc.
17.3.3. Catalyst Pharmaceuticals, Inc.
17.3.4. Cytokinetics, Incorporated
17.3.5. F. Hoffmann-La Roche Ltd.
17.3.6. Ionis Pharmaceuticals, Inc.
17.3.7. Natera Inc.
17.3.8. NMD PHARMA A/S
17.3.9. Novartis AG
17.3.10. Novo Nordisk A/S
17.3.11. PerkinElmer, Inc.
17.3.12. Pfizer Inc.
17.3.13. PTC Therapeutics, Inc.
17.3.14. Scholar Rock, Inc.
17.3.15. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. SPINAL MUSCULAR ATROPHY TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. SPINAL MUSCULAR ATROPHY TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY EMERGING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY NUSINERSEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RISDIPLAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ONASEMNOGENE ABEPARVOVEC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH PIPELINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1 (INFANTILE), BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY EARLY INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PROGRESSION MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1 (INFANTILE), 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2 (INTERMEDIATE), BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY MOBILITY MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORTHOPEDIC INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2 (INTERMEDIATE), 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3 (JUVENILE), BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHYSICAL ACTIVITY ADAPTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3 (JUVENILE), 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4 (ADULT), BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADAPTIVE DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY THERAPEUTIC MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4 (ADULT), 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY MARKETED BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PIPELINE DEVELOPMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY APPROVED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY FAMILY CAREGIVERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME HEALTH AGENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PEDIATRIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COMMERCIAL MARKETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DAYCARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITAL-BASED CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME INFUSION SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TEENAGERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY OLDER ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PRESCHOOL KIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SCHOOL AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BABIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY NEONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1 (INFANTILE), 2018-2030 (USD MILLION)
TABLE 104. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2 (INTERMEDIATE), 2018-2030 (USD MILLION)
TABLE 105. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3 (JUVENILE), 2018-2030 (USD MILLION)
TABLE 106. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4 (ADULT), 2018-2030 (USD MILLION)
TABLE 107. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1 (INFANTILE), 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2 (INTERMEDIATE), 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3 (JUVENILE), 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4 (ADULT), 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1 (INFANTILE), 2018-2030 (USD MILLION)
TABLE 159. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2 (INTERMEDIATE), 2018-2030 (USD MILLION)
TABLE 160. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3 (JUVENILE), 2018-2030 (USD MILLION)
TABLE 161. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4 (ADULT), 2018-2030 (USD MILLION)
TABLE 162. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 180. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 181. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 182. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 183. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 184. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 185. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1 (INFANTILE), 2018-2030 (USD MILLION)
TABLE 186. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2 (INTERMEDIATE), 2018-2030 (USD MILLION)
TABLE 187. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3 (JUVENILE), 2018-2030 (USD MILLION)
TABLE 188. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4 (ADULT), 2018-2030 (USD MILLION)
TABLE 189. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 190. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 191. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 192. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 193. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 195. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 196. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 197. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 198. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 199. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 204. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 205. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 206. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 207. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 209. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 210. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 211. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 212. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1 (INFANTILE), 2018-2030 (USD MILLION)
TABLE 213. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2 (INTERMEDIATE), 2018-2030 (USD MILLION)
TABLE 214. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3 (JUVENILE), 2018-2030 (USD MILLION)
TABLE 215. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4 (ADULT), 2018-2030 (USD MILLION)
TABLE 216. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 218. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 219. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 220. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 222. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 223. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 224. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 225. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 226. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 231. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 232. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 233. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 235. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 236. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 237. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 238. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 239. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1 (INFANTILE), 2018-2030 (USD MILLION)
TABLE 240. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2 (INTERMEDIATE), 2018-2030 (USD MILLION)
TABLE 241. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3 (JUVENILE), 2018-2030 (USD MILLION)
TABLE 242. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4 (ADULT), 2018-2030 (USD MILLION)
TABLE 243. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 244. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 245. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 246. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 247. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 249. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 250. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 251. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 252. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 253. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 258. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 259. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 260. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 261. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1 (INFANTILE), 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2 (INTERMEDIATE), 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3 (JUVENILE), 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4 (ADULT), 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 278. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 280. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADOLESCENTS, 2018-2030 (USD MILLION)
TABLE 286. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 287. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 288. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 289. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 290. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ENZYME

Companies Mentioned

  • Astellas Pharma Inc.
  • Biogen Inc.
  • Catalyst Pharmaceuticals, Inc.
  • Cytokinetics, Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Natera Inc.
  • NMD PHARMA A/S
  • Novartis AG
  • Novo Nordisk A/S
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Scholar Rock, Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market Report and Forecast 2024-2032 - Product Image

Spinal Muscular Atrophy Treatment Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Spinal Muscular Atrophy - Global Strategic Business Report - Product Image

Spinal Muscular Atrophy - Global Strategic Business Report

  • Report
  • 189 Pages
  • Global
From
Spinal Muscular Atrophy Market Report 2025 - Product Image

Spinal Muscular Atrophy Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Spinal Muscular Atrophy Medicine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Spinal Muscular Atrophy Medicine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 95 Pages
  • Global
From

About the Spinal Muscular Atrophy Drug Market

Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and wasting. As a result, individuals with SMA experience difficulty with activities of daily living, such as walking, eating, and breathing. Treatment for SMA is focused on managing symptoms and slowing the progression of the disease. The SMA drug market is a subset of the Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological disorders, including SMA. Currently, there are several drugs approved for the treatment of SMA, including Spinraza, Zolgensma, and Evrysdi. These drugs are designed to slow the progression of the disease and improve the quality of life for those affected. Some of the companies in the SMA drug market include Biogen, Novartis, AveXis, and Roche. These companies are actively researching and developing new treatments for SMA, as well as providing access to existing treatments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.